As rumors circulate in Washington, DC that President Donald Trump is weighing a set of measures to control rising drug costs, ASCO, the nation’s largest group of oncologists, has called for efforts to reach a consensus on drug value to ensure affordability and access for patients and spur manufacturers to work harder on bringing innovative medicines to market.
Although it may seem that pharmaceutical companies have control of the market and can charge what they like, Polite said that this cannot continue forever. “The manufacturers understand that they have a target on them and that either they come to the table and try to come up with prices that are reasonable or they’re going to have solutions imposed on them at some point.”
Kumar H, Fojo T, Mailankody S. An appraisal of clinically meaningful outcomes guidelines for oncology clinical trials. JAMA Oncol. 2016;2(9):1238-1240.
... to read the full story